Prelude Therapeutics Inc Aktie News

PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg); Company to provide an update with preliminary clinical data, including PK/PD, safety and initial clinical activity by year end 2025 Phase 1 study of PRT3789, a once weekly IV SMARCA2 degrader, has been completed; Company to provide final data by year end 2025 Prelude is advancing a development ...

WILMINGTON, Del., June 02, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in two upcoming healthcare conferences in June.

PRT3789 monotherapy and combination with docetaxel escalation enrollment is complete and the Company plans to present updated results in the second half of 2025 Enrollment of the Phase 1 study of Prelude's once daily, oral SMARCA2 degrader, PRT7732 is advancing rapidly, and an initial data update is anticipated in the second half of 2025 Current cash runway into the second quarter of 2026 with ...

WILMINGTON, Del., May 01, 2025 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Prelude) (Nasdaq: PRLD), a clinical-stage precision oncology company, announced today that the Company will participate in the Citizens Life Sciences Conference taking place in New York on May 7, 2025.

Preclinical data elucidating the mechanism of action of PRT3789, Prelude's first-in-class, highly selective SMARCA2 degrader currently in early clinical development